Core Insights - RxSight, Inc. reported a total revenue of $33.6 million for Q2 2025, a 4% decrease from $34.9 million in Q2 2024, with LAL revenue increasing by 13% and LDD revenue decreasing by 50% [4][10] - The company aims to accelerate growth through enhanced customer engagement and strategic expansion of its installed base, supported by a newly launched Customer Success Organization [3] Financial Performance - Gross profit for Q2 2025 was $25.2 million, representing 74.9% of revenue, an increase from $24.3 million or 69.5% of revenue in Q2 2024 [5] - Total operating expenses for Q2 2025 were $39.2 million, a 20% increase from $32.6 million in Q2 2024, reflecting investments in LAL sales and R&D [6] - The net loss for Q2 2025 was $(11.8) million, or $(0.29) per share, compared to a net loss of $(6.1) million, or $(0.16) per share in Q2 2024 [7] Cash Position - Cash, cash equivalents, and short-term investments decreased by $1.8 million to $227.5 million as of June 30, 2025, compared to $229.3 million as of March 31, 2025 [8] Guidance - The company reiterated its 2025 full-year revenue guidance of $120.0 million to $130.0 million, indicating a decrease of 14% to 7% compared to 2024 [9][14]

Completed Merger with Logan Ridge Finance Corporation Reports Net Investment Income of $4.6 Million, or $0.50 Per Share for the Second Quarter Announces Third Quarter 2025 Quarterly Base Distribution of $0.47 Per Share and Supplemental Distribution of $0.02 per share NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Portman Ridge Finance Corporation (Nasdaq: PTMN) (the “Company” or “Portman Ridge”) announced today its financial results for the second quarter ended June 30, 2025. Transformational Milestone On July ...

Announced strategic partnership with Simcere Zaiming for Phase 1 program SIM0505 (CDH6 ADC) with plans to dose the first SIM0505 patient in the United States this quarter Currently in cohort 4 of the Phase 1 trial of LNCB74 (B7-H4 ADC) in multiple cancersPlan to provide SIM0505 and LNCB74 program updates by the fourth quarter of 2025, along with proof of concept data readouts in the first half of 2026 BELTSVILLE, Md., Aug. 07, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharm ...

NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) -- StepStone Group Inc. (Nasdaq: STEP), a global private markets investment firm focused on providing customized investment solutions and advisory and data services, today reported results for the quarter ended June 30, 2025. This represents results for the first quarter of the fiscal year ending March 31, 2026. The Board of Directors of the Company has declared a quarterly cash dividend of $0.28 per share of Class A common stock, payable on September 15, 2025, to th ...

Fiscal 2025 revenue grew 12.0%, fueled by 53% growth in Core IoT product sales Synaptics' Board of Directors approved a new share repurchase program of up to $150 million Fiscal 2025 Financial Highlights Revenue of $1.074 billion increased 12% year-over-yearCore IoT product sales grew by 53% year-over-yearGAAP loss per share of $1.22Non-GAAP diluted earnings per share increased 61% to $3.62Repurchased $128 million (or approximately 1.8 million) sharesReduced gross debt by approximately 14% or $134 million Q ...

MENLO PARK, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended June 30, 2025. Second quarter results: Q2 2025Q2 2024Revenue$39.8 million$36.0 millionInstrument revenue$14.2 million$14.7 millionConsumable revenue$18.9 million$17.0 millionService and other revenue$6.7 million<td style="border-top: solid black 1p ...

MENLO PARK, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today reported financial results for the second quarter ended June 30, 2025, and raised its revenue guidance while reaffirming its adjusted operating expense guidance, both for full year 2025. Recent Financial and Busines ...

SPRINGDALE, Ark., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Tyson Foods, Inc. (NYSE: TSN) announced today that its board of directors has declared a quarterly dividend of $0.50 per share on Class A common stock and $0.45 per share on Class B common stock, payable on December 15, 2025, to shareholders of record at the close of business on December 1, 2025. Additionally, effective as of today, the board of directors approved an increase of 43 million shares authorized for repurchase under the company’s share repurcha ...

Revenue of $666 million in the Second Quarter, down 3% Year-over-YearPrivate Cloud Revenue was $250 million, down 4% Year-over-YearPublic Cloud Revenue was $417 million, down 2% Year-over-YearSecond Quarter 2025 Cash Flow From Operating Activities was $8 million; Cash Flow From Operating Activities was $127 million on a Trailing-Twelve-Month Basis SAN ANTONIO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Rackspace Technology, Inc. (Nasdaq: RXT), a leading end-to-end, hybrid cloud and AI solutions company, today announ ...

BEACON-IPF close out activities continue Previously announced workforce and operational realignment largely complete Phase 1 oncology trial on track to deliver additional data by the end of the year SOUTH SAN FRANCISCO, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in integrin-based drug development, today provided a corporate update and reported second quarter 2025 financial results. “While our activities in the quarter ...